AtriCure Issues FY Adjusted EBITDA Outlook
AtriCure's fiscal-year adjusted EBITDA outlook is USD 91–94 million, versus the IBES estimate of USD 87.5 million.
Related stories
Kadant Q3 Adjusted EPS Rises to USD 3.64, Above IBES Estimate
Kadant reported a Q3 gross margin of 44.7%.
M impact | EARNINGS | Nov 03, 2026, 09:48 PM UTC
Ternium Swings to Third-Quarter Profit
M impact | EARNINGS | Nov 03, 2026, 09:42 PM UTC
PayPay Fiscal Q2 EPS 25.42 Yen vs FactSet Estimate 32.59 Yen
PayPay reported fiscal Q2 EPS of 25.42 Japanese yen, compared with the FactSet estimate of 32.59 yen.
M impact | EARNINGS | Nov 03, 2026, 09:41 PM UTC
Kadant Q3 Adjusted EBITDA Is $72 Million vs. $64.4 Million Estimate
Kadant reported Q3 adjusted EBITDA of $72 million, compared with the IBES estimate of $64.4 million.
M impact | EARNINGS | Nov 03, 2026, 09:41 PM UTC
Kadant reports Q3 net income of USD 35 million
L impact | EARNINGS | Nov 03, 2026, 09:41 PM UTC
Ternium Turns Profitable in Third Quarter
Ternium reported net profit in the third quarter, compared with a loss a year earlier. Net sales were higher year over year, but the amount is not provided.
M impact | EARNINGS | Nov 03, 2026, 09:41 PM UTC